Novartis Seals $3.1B Deal to Acquire Anthos

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its cardiovascular pipeline.
Novartis agrees to acquire Anthos for up to $3.1 billion
Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, the companies said on Tuesday.
M&A News: Novartis Seals $3.1B Deal to Acquire Anthos
Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. Novartis will pay an
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease.
Blackstone sells Anthos to Novartis for up to $3.1bn
Blackstone Life Sciences has sold Anthos Therapeutics to Novartis for up to $3.1 billion. Anthos is a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases. It is based in Boston.
Novartis buys Blackstone's Anthos for up to $3.1bln
Anthos was founded by private equity firm Blackstone's Life Sciences business and by Novartis in 2019 to develop, manufacture, and commercialise abelacimab, a treatment to prevent strokes and the recu
Novartis to Buy Anthos Therapeutics for $925 Million
Novartis AG has agreed to acquire Anthos Therapeutics for $925 million as the European drug giant seeks to bolster its late-stage cardiovascular pipeline.
Novartis to acquire Anthos for up to US$3.1 billion
Swiss pharmaceutical giant Novartis said on Tuesday (Feb 11) it has agreed to acquire biopharma firm Anthos Therapeutics for up to US$3.1 billion. Read more at The Business Times.
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Blackstone Life Sciences and Anthos Therapeutics, Inc. ("Anthos" or the "company"), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases,
MM&M3d
Novartis’ chief marketing officer on the drugmaker’s Super Bowl ad debut
Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...
FiercePharma19h
Novartis debuts €40M viral vector plant in Slovenia, part of €3.5B investment push in the country
Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...
Super Bowl Highlights Breast Cancer Awareness In Novartis Commercial With Wanda Sykes
The Super Bowl tackled breast cancer awareness in a new Novartis Commercial featuring survivor and comedian Wanda Sykes.
Novartis beats Q4 earnings consensus as drug sales surge
Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...
Novartis Wins at the 2025 Kellogg School Super Bowl Advertising Review
Novartis took home the top spot in the 21st Kellogg School Super Bowl Advertising Review with its "Your Attention, Please" ad putting a spotlight on breast health and encouraging cancer screening – ...
Bangladesh Sangsbad Sangstha18h
Writ seeking probe Novartis share transfer removed from cause list
DHAKA, Feb 10, 2025 (BSS) - The writ petition regarding the transfer of shares of Novartis Bangladesh Limited has been ...
Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
Is Novartis AG (NVS) The Best Annual Dividend Stock To Buy Now?
We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...